BACKGROUND: BST2/tetherin is an innate immune molecule with the unique ability to restrict the egress of human immunodeficiency virus (HIV) and other enveloped viruses, including Ebola virus (EBOV). Coincident with this discovery was the finding that the HIV Vpu protein down-regulates BST2 from the cell surface, thereby promoting viral release. Evidence suggests that the EBOV envelope glycoprotein (GP) also counteracts BST2, although the mechanism is unclear. RESULTS: We find that total levels of BST2 remain unchanged in the presence of GP, whereas surface BST2 is significantly reduced. GP is known to sterically mask surface receptors via its mucin domain. Our evaluation of mutant GP molecules indicate that masking of BST2 by GP is probably responsible for the apparent surface BST2 down-regulation; however, this masking does not explain the observed virus-like particle egress enhancement. We discovered that VP40 coimmunoprecipitates and colocalizes with BST2 in the absence but not in the presence of GP. CONCLUSIONS: These results suggest that GP may overcome the BST2 restriction by blocking an interaction between VP40 and BST2. Furthermore, we have observed that GP may enhance BST2 incorporation into virus-like particles. Understanding this novel EBOV immune evasion strategy will provide valuable insights into the pathogenicity of this deadly pathogen.
BACKGROUND: BST2/tetherin is an innate immune molecule with the unique ability to restrict the egress of human immunodeficiency virus (HIV) and other enveloped viruses, including Ebola virus (EBOV). Coincident with this discovery was the finding that the HIV Vpu protein down-regulates BST2 from the cell surface, thereby promoting viral release. Evidence suggests that the EBOV envelope glycoprotein (GP) also counteracts BST2, although the mechanism is unclear. RESULTS: We find that total levels of BST2 remain unchanged in the presence of GP, whereas surface BST2 is significantly reduced. GP is known to sterically mask surface receptors via its mucin domain. Our evaluation of mutant GP molecules indicate that masking of BST2 by GP is probably responsible for the apparent surface BST2 down-regulation; however, this masking does not explain the observed virus-like particle egress enhancement. We discovered that VP40 coimmunoprecipitates and colocalizes with BST2 in the absence but not in the presence of GP. CONCLUSIONS: These results suggest that GP may overcome the BST2 restriction by blocking an interaction between VP40 and BST2. Furthermore, we have observed that GP may enhance BST2 incorporation into virus-like particles. Understanding this novel EBOV immune evasion strategy will provide valuable insights into the pathogenicity of this deadly pathogen.
Authors: Sheli R Radoshitzky; Lian Dong; Xiaoli Chi; Jeremiah C Clester; Cary Retterer; Kevin Spurgers; Jens H Kuhn; Sarah Sandwick; Gordon Ruthel; Krishna Kota; Dutch Boltz; Travis Warren; Philip J Kranzusch; Sean P J Whelan; Sina Bavari Journal: J Virol Date: 2010-08-04 Impact factor: 5.103
Authors: Constantin Brinkmann; Inga Nehlmeier; Kerstin Walendy-Gnirß; Julia Nehls; Mariana González Hernández; Markus Hoffmann; Xiangguo Qiu; Ayato Takada; Michael Schindler; Stefan Pöhlmann Journal: J Virol Date: 2016-11-28 Impact factor: 5.103
Authors: Joseph B Prescott; Andrea Marzi; David Safronetz; Shelly J Robertson; Heinz Feldmann; Sonja M Best Journal: Nat Rev Immunol Date: 2017-01-23 Impact factor: 53.106
Authors: Shuzo Urata; Elizabeth Kenyon; Debasis Nayak; Beatrice Cubitt; Yohei Kurosaki; Jiro Yasuda; Juan C de la Torre; Dorian B McGavern Journal: PLoS Pathog Date: 2018-07-20 Impact factor: 6.823
Authors: Mahesh Chemudupati; Adam D Kenney; Serena Bonifati; Ashley Zani; Temet M McMichael; Li Wu; Jacob S Yount Journal: Biochim Biophys Acta Mol Cell Res Date: 2018-10-02 Impact factor: 4.739